Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of Fluciclovine (18F) PET on the Management of Participants With Prostate Cancer Following Negative or Equivocal PSMA PET Imaging at the Time of Biochemical Recurrence

NCT07569926 is registered in ClinicalTrials.gov with Blue Earth Diagnostics as lead sponsor.

NCT NCT07569926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07569926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of Fluciclovine (18F) PET on the Management of Participants With Prostate Cancer Following Negative or Equivocal PSMA PET Imaging at the Time of Biochemical Recurrence
Lead sponsor
Blue Earth Diagnostics
Phase
Phase 4
Overall status
Recruiting
Start date
August 31, 2026
Completion date
December 31, 2032
Enrollment
142 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer